Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new NIHR funded trial will compare whether either fixing the broken bone or replacing the hip joint gives a better result for people over 60

© Twinsterphoto/Shutterstock

Every year around 70,000 people in the UK, and 1.3 million globally, break their hip. Facing increasingly ageing populations these numbers are projected to rise to more than 100,000 by 2020 in the UK. The problem is estimated to cause the loss of 1.75 million disability adjusted life years per year globally, and represents 1.4% of the total healthcare burden in established market economies.

A new study, FRUITI, will look at treatments for one specific type of hip fracture. Minimally displaced intracapsular fractures, those that occur at the head of the femur, and may have loss of blood supply to the bone, represent approximately ten to fifteen per cent of all hip fractures. Currently, there are two treatments available. Surgeons either repair the fracture with screws or remove and replace the broken piece of bone, but it's not known which is better for patients.

Xavier Griffin, Associate Professor of Trauma Surgery at NDORMS, University of Oxford, explained: "Treatment of this type of fracture by fixing the broken bone is a quick procedure which has the advantage of preserving the patient's own hip joint. However, healing can be unsuccessful with patients requiring revision surgery in perhaps 30% of cases. Hip replacement surgery eliminates the risk of fixation failure as the femoral neck is replaced. But it is a more major operation with very significant complications of its own including a greater risk of infection, dislocation and periprosthetic fracture."

Developed by a team of patient representatives, clinical experts in trauma orthopaedics, study management specialists, experienced statisticians and health economists, the study will compare the two treatments for people 60 years and over. They will recruit 878 people to the study from 40 hospitals across the UK, and review patients health, walking ability and other daily activities, as well as any complications and specific costs at the outset, and at 6 weeks, 4 months and 1 year after the injury.

Fruiti is funded by the National Institute for Health Research (NIHR).

MEET THE TEAM

NIHR Funded by Feb2019

Similar stories

NDORMS researchers win prestigious national leadership prizes

Professor of Orthopaedic Trauma Matthew Costa and NIHR Doctoral Research Fellow Rachel Kuo were announced among the winners of the NIHR20 Research Leaders Prizes in recognition of their outstanding contribution to health and care research.

From Paraguay to Oxford: Mariela’s experience of the Trueta Bursary

Mariela Ortiz, a pharmacist from Paraguay received a Trueta Bursary to attend the Botnar Institute's Summer School in Real World Evidence this June.

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

NDORMS student wins national research prize

A medical student at NDORMS has gained a top prize in the prestigious 2026 Falk Foundation/Guts UK Charity national awards. Sara Lyden won the Medical Student Prize for her research project, ‘Integrating histo-molecular patient profiles with patient reported symptoms and quality of life measures in ulcerative colitis.’

Trial exploring effects of drug on liver in psoriasis patients recruits first UK patient

The first patient in the UK has been recruited to a clinical trial investigating how a new drug affects liver inflammation and scarring in people with psoriatic disease using a new non-invasive MRI scanning technique.